{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T08:42:59Z","timestamp":1769589779383,"version":"3.49.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Adult-onset Still\u2019s disease (AOSD) is a rare inflammatory disease characterized by a classic triad of daily spike fever, arthritis, and a typical salmon-pink rash. The involvement of inflammatory cytokines by various factors such as infection, drug, or neoplasm causes refractory AOSD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We report a 63-year-old man with a high fever, rash, hyperferritinemia, and M proteinemia. His serum levels of interleukin-6 and interleukin-18 were remarkably high at 192 and 114,250 pg\/mL, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>AOSD complicated with monoclonal gammopathy of undetermined significance was diagnosed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>After steroid pulse therapy followed by oral prednisolone, cyclosporin, methotrexate, and colchicine, serum ferritin levels temporarily declined, but secondary cytomegalovirus infections exacerbated AOSD\u2019s activity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Finally, after tocilizumab induction, AOSD activity was gradually suppressed over a long period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>The disease activity of AOSD is exacerbated by multiple factors, including comorbidities or infections. Clinicians need to consider that monoclonal gammopathy of undetermined significance complications might become AOSD refractory by an elevation of the inflammatory cytokines. Moreover, further prospective studies are required to confirm this result.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032107","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T21:30:03Z","timestamp":1673559003000},"page":"e32107","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Refractory adult-onset Still\u2019s disease complicated with monoclonal gammopathy of undetermined significance: A case report"],"prefix":"10.1097","volume":"101","author":[{"given":"Kenji","family":"Saito","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ohkawara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukushima Medical University School of Medicine, Fukushima, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Sumichika","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumpei","family":"Temmoku","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Yashiro-Furuya","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuzo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Migita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12016-019-08747-8","article-title":"Autoinflammatory pathogenesis and targeted therapy for adult-onset still\u2019s disease","volume":"58","author":"Li","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13075-020-02200-4","article-title":"Interleukin-18 and fibroblast growth factor 2 in combination is a useful diagnostic biomarker to distinguish adult-onset Still\u2019s disease from sepsis","volume":"22","author":"Koga","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/rheumatology\/keq284","article-title":"Potential role of Th17 cells in the pathogenesis of adult-onset Still\u2019s disease","volume":"49","author":"Chen","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/mr\/roab004","article-title":"Interluekin-6 inhibitors for the treatment of adult-onset Still\u2019s disease","volume":"32","author":"Kaneko","year":"2021","journal-title":"Mod Rheumatol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3899\/jrheum.130575","article-title":"Interleukin 18: a biomarker for differential diagnosis between adult-onset Still\u2019s disease and sepsis","volume":"41","author":"Priori","year":"2014","journal-title":"J Rheumatol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/1529-0131(200107)44:7<1716::AID-ART298>3.0.CO;2-I","article-title":"Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still\u2019s disease","volume":"44","author":"Kawaguchi","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0889-8588(05)70416-0","article-title":"Monoclonal gammopathy of undetermined significance and solitary plasmacytoma. Implications for progression to overt multiple myeloma","volume":"11","author":"Kyle","year":"1997","journal-title":"Hematol Oncol Clin North Am"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2141.2000.01963.x","article-title":"Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma","volume":"109","author":"Zheng","year":"2000","journal-title":"Br J Haematol"},{"key":"R10-20250504","first-page":"424","article-title":"Preliminary criteria for classification of adult Still\u2019s disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s13104-018-3420-8","article-title":"Adding colchicine to immunosuppressive treatments; a potential option for biologics-refractory adult-onset Still\u2019s disease","volume":"11","author":"Asano","year":"2018","journal-title":"BMC Res Notes"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.3390\/ijms20112822","article-title":"Lymphocyte subsets and inflammatory cytokines of monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"20","author":"Allegra","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12026-014-8561-9","article-title":"Pathogenesis of adult-onset Still\u2019s disease: new insights from the juvenile counterpart","volume":"61","author":"Jamilloux","year":"2015","journal-title":"Immunol Res"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13075-017-1406-x","article-title":"Effects of HLA-DRB1 alleles on susceptibility and clinical manifestations in Japanese patients with adult onset Still\u2019s disease","volume":"19","author":"Asano","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/14397595.2018.1514999","article-title":"HLA-DQB1 DPB1 alleles in Japanese patients with adult-onset Still\u2019s disease","volume":"29","author":"Fujita","year":"2019","journal-title":"Modern Rheumatol\/ the Japan Rheumatism Assoc"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.4049\/jimmunol.1302549","article-title":"Cutting edge: endoplasmic reticulum stress licenses macrophages to produce mature IL-1\u03b2 in response to TLR4 stimulation through a caspase-8- and TRIF-dependent pathway","volume":"192","author":"Shenderov","year":"2014","journal-title":"J Immunol"},{"key":"R19-20250504","first-page":"396","article-title":"Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still\u2019s disease","volume":"25","author":"Hoshino","year":"1998","journal-title":"J Rheumatol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1136\/ard.2003.013680","article-title":"Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset still\u2019s disease","volume":"63","author":"Chen","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5","article-title":"Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still\u2019s disease","volume":"44","author":"Kawashima","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/14397595.2018.1465633","article-title":"Evidence-based clinical practice guideline for adult still\u2019s disease","volume":"28","author":"Mimura","year":"2018","journal-title":"Modern Rheumatol\/ Japan Rheumatism Assoc"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/blood.V82.2.564.564","article-title":"Identification of immature and mature myeloma cells in the bone marrow of human myelomas","volume":"82","author":"Kawano","year":"1993","journal-title":"Blood"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood.V96.12.3880","article-title":"The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells","volume":"96","author":"Rawstron","year":"2000","journal-title":"Blood"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/blood-2013-12-546374","article-title":"Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma","volume":"123","author":"San-Miguel","year":"2014","journal-title":"Blood"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1182\/blood-2014-02-554071","article-title":"TPL2 kinase regulates the inflammatory milieu of the myeloma niche","volume":"123","author":"Hope","year":"2014","journal-title":"Blood"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ccell.2018.02.007","article-title":"Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment","volume":"33","author":"Nakamura","year":"2018","journal-title":"Cancer Cell"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still\u2019s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/art.30238","article-title":"Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis","volume":"63","author":"Vojinovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.semarthrit.2017.06.006","article-title":"Adult onset still\u2019s disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review)","volume":"47","author":"Junge","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R36-20250504","first-page":"12","article-title":"Monoclonal gammopathy and rheumatic diseases","volume":"39","author":"Raposo","year":"2014","journal-title":"Acta Reumatol Port"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.semarthrit.2015.10.003","article-title":"Adult onset Still\u2019s disease associated with malignancy-cause or coincidence?","volume":"45","author":"Hofheinz","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-med-061813-012806","article-title":"Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies","volume":"66","author":"Schulert","year":"2015","journal-title":"Annu Rev Med"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3389\/fimmu.2019.00898","article-title":"Cytomegalovirus infection may trigger adult-onset still\u2019s disease onset or relapses","volume":"10","author":"Jia","year":"2019","journal-title":"Front Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:48:41Z","timestamp":1746334121000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":40,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032107","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]}}}